Spero Therapeutics, Inc. cotiza a 1.18 USD y tiene una capitalización bursátil de $69M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbap…
| Periodo | 2026-11 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | — | $-0.13 | $-0.03 | $-0.25 |
| Estimado | $-0.18 | $-0.25 | $-0.38 | $-0.44 |
| Sorpresa | — | +48.0% | +92.1% | +43.2% |
| Métrica | SPRO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 9.4% | -38.6% | +48.1% |
| Net Margin | 12.8% | -33.6% | +46.4% |
| FCF Margin | — | -13.9% | — |
| ROE | 14.5% | -40.4% | +54.9% |
| ROA | 12.4% | -32.0% | +44.4% |
| Current Ratio | 7.59 | 2.84 | +4.75 |
| Debt / Equity | — | 0.28 | — |